company background image
6652 logo

Eusol BiotechLtd TPEX:6652 Stock Report

Last Price

NT$9.79

Market Cap

NT$1.3b

7D

7.6%

1Y

-33.2%

Updated

28 Mar, 2024

Data

Company Financials

6652 Stock Overview

Eusol Biotech Co.,Ltd. focuses on research and development of new biotech drugs for sleep disorders.

6652 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Eusol Biotech Co.,Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eusol BiotechLtd
Historical stock prices
Current Share PriceNT$9.79
52 Week HighNT$14.95
52 Week LowNT$8.56
Beta-0.22
1 Month Change4.59%
3 Month Change3.49%
1 Year Change-33.17%
3 Year Change-60.44%
5 Year Change-52.24%
Change since IPO-77.44%

Recent News & Updates

Recent updates

We Think EUSOL Biotech (GTSM:6652) Can Afford To Drive Business Growth

Jan 20
We Think EUSOL Biotech (GTSM:6652) Can Afford To Drive Business Growth

Shareholder Returns

6652TW BiotechsTW Market
7D7.6%0.3%1.9%
1Y-33.2%-21.1%26.7%

Return vs Industry: 6652 underperformed the TW Biotechs industry which returned -21.1% over the past year.

Return vs Market: 6652 underperformed the TW Market which returned 26.7% over the past year.

Price Volatility

Is 6652's price volatile compared to industry and market?
6652 volatility
6652 Average Weekly Movement6.4%
Biotechs Industry Average Movement4.3%
Market Average Movement4.2%
10% most volatile stocks in TW Market8.0%
10% least volatile stocks in TW Market1.9%

Stable Share Price: 6652 has not had significant price volatility in the past 3 months.

Volatility Over Time: 6652's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
1994n/aHong-Jen Changhttps://www.eusol-biotech.com

Eusol Biotech Co.,Ltd. focuses on research and development of new biotech drugs for sleep disorders. Its pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for repairing neuron function; and SM-1, a 3-in-1 capsule containing 3 commercial drugs with sedative effect.

Eusol Biotech Co.,Ltd. Fundamentals Summary

How do Eusol BiotechLtd's earnings and revenue compare to its market cap?
6652 fundamental statistics
Market capNT$1.34b
Earnings (TTM)-NT$327.00k
Revenue (TTM)n/a

0.0x

P/S Ratio

-4,102x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6652 income statement (TTM)
RevenueNT$0
Cost of RevenueNT$0
Gross ProfitNT$0
Other ExpensesNT$327.00k
Earnings-NT$327.00k

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0024
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 6652 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.